Test Price
2,800 AEDโ Home Collection Available
KCNQ2 Genetic Test (Early Infantile Epileptic Encephalopathy Type 7) in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity: ISO 9001:2015 accredited processing ensures unparalleled accuracy across all coding regions.
- VIP Mobile Phlebotomy: Temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Post-Test Consultation: Telephonic result interpretation by our Consultant Medical Genetics team.
- Insurance & Compliance: Direct verification via WhatsApp +971 54 548 8731. Full adherence to Federal Decree-Law No. 45 of 2021 (PDPL) and genetic data confidentiality.
Test Overview & Methodology
The KCNQ2 NGS test analyzes the gene responsible for early infantile epileptic encephalopathy type 7, a severe neonatal-onset epilepsy disorder. This advanced DNA sequencing detects pathogenic variants to guide precise diagnosis and personalized treatment. Utilising next-generation sequencing technology, the assay provides comprehensive coverage of the KCNQ2 coding region and splice sites, enabling identification of point mutations, small insertions, and deletions with high sensitivity and specificity.
| Parameter | Our Test (NGS ISO-Certified) | Closest Alternative (Conventional Sanger Sequencing) |
|---|---|---|
| Molecular Detection Rate | 99.9% (high-depth NGS coverage) | 85โ90% (limited to coding regions) |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
| Accreditation | ISO 9001:2015 & DHA Licensed | Variable / Non-ISO |
| Pre-test Genetic Counselling | Included (Pedigree Analysis) | Often Not Provided |
Physician Insight & Safety Protocols
"KCNQ2 pathogenic variants cause a devastating early-onset epilepsy, but precision diagnosis opens the door to targeted therapies and improved neurodevelopmental outcomes. Families facing this diagnosis are never aloneโour multidisciplinary team provides expert interpretation and compassionate support every step of the way."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Safety Advisory
- Medication Warning: Do not discontinue prescribed antiepileptic drugs without consulting your treating physician. This test does not replace acute seizure management.
- Emergency Red Flags: If your child experiences status epilepticus, respiratory depression, or sudden worsening of seizures, seek immediate emergency medical care.
Exclusion Criteria
- Active febrile illness or severe coagulopathy contraindicating blood draw.
- Inability to provide informed consent (guardian consent mandatory for minors per Federal Decree-Law No. 4 of 2016 on Medical Liability).
Patient FAQ & Clinical Guidance
1. What is the KCNQ2 genetic test for early infantile epileptic encephalopathy type 7?
This NGS test identifies pathogenic mutations in the KCNQ2 gene causing severe neonatal epilepsy, enabling tailored antiepileptic therapy and precision management of seizures and developmental outcomes.
2. Who should consider this test?
Infants presenting with drug-resistant seizures, developmental delay, or a family history of early-onset epilepsy should undergo KCNQ2 testing for definitive diagnosis and to guide targeted treatment planning.
3. How is the test performed and what is the turnaround time?
A simple peripheral blood draw or FTA card sample is analyzed using next-generation sequencing. Results are reported within 3 to 4 weeks from sample receipt.
UAE Regulatory & Data Privacy Adherence
Regulatory & Data Privacy Compliance
- DNA Labs UAE operates under DHA Facility License No. 1143.
- All genetic data is processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health information handling adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Patient consent and clinical safety follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | KCNQ2 Genetic Test (Early Infantile Epileptic Encephalopathy Type 7) |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | G40.4 |
| LOINC Code | 94231-0 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians